NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP
QuidelOrtho Corp. QDEL
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.7B
▼ 1.9% vs FY2024
EPS · FY25
$-16.69
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-46.1%
Net margin · FY25
-41.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.7B
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 41 cents on every revenue dollar this year.
Per share
USD -16.69
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-46.1%
Return on equity, FY2025
ROE
Operating margin-33.7%
Net margin-41.5%
Return on assets-18.6%
Each USD of equity lost 46 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -6.1M
Share of profit-0.0%
Consecutive raises—
Growth
+10.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−5.8%
+10.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.8B
total assets, end of FY2025
Total assetsUSD 5.8B
EquityUSD 1.9B
CashUSD 169.8M
Gross debtUSD 2.9B
Net debtUSD 2.7B
Current ratio1.50×
Net debt stands at 141% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
2.7
2.8
3.0
3.3
1.7
1.7
Operating income $B
−0.9
−2.0
0.1
0.8
0.9
1.1
EBITDA $B
−0.5
−1.5
0.6
1.1
1.0
1.1
Income tax $B
0.0
−0.1
−0.0
0.2
0.2
0.2
Net income $B
−1.1
−2.1
−0.0
0.5
0.7
0.8
EPS, diluted $
−16.69
−30.54
−0.15
9.56
16.43
18.60
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−46.1
−51.4
−0.2
16.0
43.2
60.8
Shares out B
0.07
0.07
0.07
0.07
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed